|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
41,504,000 |
Market
Cap: |
1.32(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$21.16 - $40.91 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 625 |
Guru Rank Value : 3 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Collegium Pharmaceutical is a pharmaceutical company. Co.'s portfolio includes: Xtampza ER, Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol. Xtampza ER was approved by the U.S. Food and Drug Administration for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. Nucynta ER is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
181,711 |
289,391 |
332,975 |
1,049,160 |
Total Sell Value |
$6,087,407 |
$9,456,240 |
$10,506,887 |
$26,725,036 |
Total People Sold |
4 |
6 |
6 |
7 |
Total Sell Transactions |
5 |
12 |
14 |
44 |
End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Ciaffoni Joseph |
President and CEO |
|
2023-06-01 |
4 |
AS |
$22.09 |
$690,758 |
D/D |
(31,272) |
306,272 |
|
6% |
|
Ciaffoni Joseph |
President and CEO |
|
2023-05-31 |
4 |
AS |
$21.87 |
$683,797 |
D/D |
(31,272) |
337,544 |
|
6% |
|
Ciaffoni Joseph |
President and CEO |
|
2023-05-30 |
4 |
AS |
$21.90 |
$684,907 |
D/D |
(31,271) |
368,816 |
|
8% |
|
Freund John Gordon |
Director |
|
2023-05-18 |
4 |
A |
$0.00 |
$0 |
D/D |
9,792 |
44,775 |
|
- |
|
Mcfarlane Neil F. |
Director |
|
2023-05-18 |
4 |
A |
$0.00 |
$0 |
D/D |
9,792 |
41,672 |
|
- |
|
Heffernan Michael Thomas |
Director |
|
2023-05-18 |
4 |
A |
$0.00 |
$0 |
D/D |
9,792 |
37,815 |
|
- |
|
Balice-Gordon Rita J. |
Director |
|
2023-05-18 |
4 |
A |
$0.00 |
$0 |
D/D |
9,792 |
38,795 |
|
- |
|
Santini Gino |
Director |
|
2023-05-18 |
4 |
A |
$0.00 |
$0 |
D/D |
9,792 |
67,963 |
|
- |
|
Melincoff Gwen A |
Director |
|
2023-05-18 |
4 |
A |
$0.00 |
$0 |
D/D |
9,792 |
44,775 |
|
- |
|
Fallon John A. |
Director |
|
2023-05-18 |
4 |
A |
$0.00 |
$0 |
D/D |
9,792 |
47,150 |
|
- |
|
Bohlin Garen G |
Director |
|
2023-05-18 |
4 |
A |
$0.00 |
$0 |
D/D |
9,792 |
44,775 |
|
- |
|
Tupper Colleen |
EVP & Chief Financial Officer |
|
2023-03-15 |
4 |
AS |
$23.77 |
$752,165 |
D/D |
(31,640) |
105,420 |
|
-7% |
|
Dreyer Scott |
EVP & Chief Commercial Officer |
|
2023-03-01 |
4 |
AS |
$26.70 |
$355,751 |
D/D |
(13,324) |
134,882 |
|
-20% |
|
Kuhlmann Shirley R. |
EVP and General Counsel |
|
2023-02-13 |
4 |
AS |
$26.88 |
$586,280 |
D/D |
(21,811) |
137,502 |
|
-16% |
|
Ciaffoni Joseph |
President and CEO |
|
2023-02-13 |
4 |
AS |
$26.88 |
$302,400 |
D/D |
(11,250) |
400,087 |
|
-16% |
|
Ciaffoni Joseph |
President and CEO |
|
2023-02-13 |
4 |
OE |
$15.90 |
$178,875 |
D/D |
11,250 |
411,337 |
|
- |
|
Kuhlmann Shirley R. |
EVP and General Counsel |
|
2023-02-10 |
4 |
D |
$26.75 |
$643,231 |
D/D |
(24,046) |
159,313 |
|
- |
|
Kuhlmann Shirley R. |
EVP and General Counsel |
|
2023-02-10 |
4 |
A |
$0.00 |
$0 |
D/D |
73,864 |
183,359 |
|
- |
|
Tupper Colleen |
EVP & Chief Financial Officer |
|
2023-02-10 |
4 |
D |
$26.75 |
$290,345 |
D/D |
(10,854) |
137,060 |
|
- |
|
Tupper Colleen |
EVP & Chief Financial Officer |
|
2023-02-10 |
4 |
A |
$0.00 |
$0 |
D/D |
57,610 |
147,914 |
|
- |
|
Ciaffoni Joseph |
President and CEO |
|
2023-02-10 |
4 |
D |
$26.75 |
$2,778,175 |
D/D |
(103,857) |
400,087 |
|
- |
|
Ciaffoni Joseph |
President and CEO |
|
2023-02-10 |
4 |
A |
$0.00 |
$0 |
D/D |
255,194 |
503,944 |
|
- |
|
Dreyer Scott |
EVP & Chief Commercial Officer |
|
2023-02-10 |
4 |
D |
$26.75 |
$570,471 |
D/D |
(21,326) |
148,206 |
|
- |
|
Dreyer Scott |
EVP & Chief Commercial Officer |
|
2023-02-10 |
4 |
A |
$0.00 |
$0 |
D/D |
66,734 |
169,532 |
|
- |
|
Smith Thomas B |
EVP and Chief Medical Officer |
|
2023-02-10 |
4 |
A |
$0.00 |
$0 |
D/D |
31,185 |
31,185 |
|
- |
|
391 Records found
|
|
Page 2 of 16 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|